Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) EPS (Weighted Average and Diluted) (2020 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$2.53 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 2.32% to -$2.53 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.83 through Dec 2025, up 41.66% year-over-year, with the annual reading at -$12.85 for FY2025, 41.32% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$2.53 at Madrigal Pharmaceuticals, up from -$5.08 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$1.9 in Q2 2025, with the low at -$7.38 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.33, with a median of -$4.19 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 74.47% in 2024, then surged 73.24% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$3.78 in 2021, then crashed by 31.75% to -$4.98 in 2022, then fell by 14.06% to -$5.68 in 2023, then soared by 54.4% to -$2.59 in 2024, then increased by 2.32% to -$2.53 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$2.53, -$5.08, and -$1.9 for Q4 2025, Q3 2025, and Q2 2025 respectively.